Piper Jaffray Companies Weighs in on ContraFect Corp’s Q1 2020 Earnings (CFRX)

ContraFect Corp (NASDAQ:CFRX) – Piper Jaffray Companies issued their Q1 2020 earnings per share estimates for ContraFect in a report issued on Thursday, March 14th. Piper Jaffray Companies analyst E. Tenthoff anticipates that the biotechnology company will earn ($0.12) per share for the quarter. Piper Jaffray Companies also issued estimates for ContraFect’s Q2 2020 earnings at ($0.13) EPS, Q3 2020 earnings at ($0.13) EPS and Q4 2020 earnings at ($0.14) EPS.

Separately, ValuEngine cut shares of ContraFect from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th.

Shares of CFRX opened at $0.40 on Friday. ContraFect has a fifty-two week low of $0.35 and a fifty-two week high of $2.93. The company has a market capitalization of $32.16 million, a PE ratio of -1.08 and a beta of -0.49.

ContraFect (NASDAQ:CFRX) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.17.

Several institutional investors and hedge funds have recently made changes to their positions in CFRX. Federated Investors Inc. PA grew its position in shares of ContraFect by 6.8% in the third quarter. Federated Investors Inc. PA now owns 6,407,500 shares of the biotechnology company’s stock valued at $13,264,000 after purchasing an additional 407,500 shares during the period. Oracle Investment Management Inc. grew its position in shares of ContraFect by 31.8% in the third quarter. Oracle Investment Management Inc. now owns 4,250,384 shares of the biotechnology company’s stock valued at $8,798,000 after purchasing an additional 1,025,651 shares during the period. Vanguard Group Inc. grew its position in shares of ContraFect by 24.2% in the third quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock valued at $5,454,000 after purchasing an additional 512,940 shares during the period. Vanguard Group Inc grew its position in shares of ContraFect by 24.2% in the third quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock valued at $5,454,000 after purchasing an additional 512,940 shares during the period. Finally, AXA grew its position in shares of ContraFect by 196.0% in the third quarter. AXA now owns 1,664,781 shares of the biotechnology company’s stock valued at $3,446,000 after purchasing an additional 1,102,264 shares during the period. 55.57% of the stock is owned by hedge funds and other institutional investors.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Further Reading: Technical Analysis of Stocks, How Can It Help

Earnings History and Estimates for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.